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Fig. 1. (A) Homocysteine and (B) vascular en-
dothelial growth factor 2 (VEGFR-2) serum lev-
els in control, hemodialyzed (HD), and kidney
transplanted (KTx) patients. *P 0.05 vs. KTx
patients; **P  0.001 vs. KTx and control pa-
tients; #P  0.001 vs. KTx patients and P 
0.014 vs. control patients.
the renin-angiotensin system. Therefore, specific dosage
of ACE-I and ARBs may be required to obtain maximal
renoprotective effects in various populations. Unfortu-
nately, the optimal dosage of ACE-I has only been investi-
gated in Japanese patients with nonrenal disease [1].
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receptor 2 serum levels in
hemodialyzed and kidney
transplanted patients
To the Editor: Homocysteine has an inhibitory effect
on angiogenesis [1]. However, the vascular endothelial
growth factor receptor-2 (VEGFR-2) gene has recently
been found up-regulated on human atherosclerotic plaques
[2]. In order to analyze the association between homocys-
teine and VEGFR-2 serum levels, we have randomly
selected 26 regular hemodialysis (HD) patients ages 56
12 years (mean  SD; M  14, F  12), and 26 age-
matched kidney transplanted individuals (KTx), ages
52  8 years (M  21, F  5). KTx transplant age was
13 9 months and creatinine was 1.6 0.5 mg/dL. Nine
age-matched healthy volunteers (47 5 years) were also
recruited. HD samples were collected at the end of the
long interval period. Serum homocysteine (Hcy) and
VEGFR-2 were tested by high-performance liquid chro-
matography (HPLC) with fluorimetric detection and a
commercial enzyme-linked immunosorbent assay (ELISA)
kit, respectively. Hcy was higher in HD patients (57 
36 mol/L) than in KTx patients (23  8 mol/L; P 
0.001) and control patients (15  6 mol/L; P  0.01
vs. HD; P  0.05 vs. KTx). VEGFR-2 was lower in HD
patients (1705 387 pg/mL) than in KTx patients (2449
825 pg/mL; P  0.014) or control patients (2150  464
pg/mL) (Fig. 1). The present study shows that Hcy and
circulating VEGFR-2 are inversely associated, consistent
with previous reports showing that homocysteine inhibits
angiogenesis. Our data also suggest that up-regulation
of the VEGFR-2 gene is probably a local finding, and that
hyperhomocysteinemia may be involved in the release of
VEGFR-2 into the systemic circulation.
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